Late effects & qual. of life

Publications 2024

Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S (2024)
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas
Med, 5 (6), 583-602.e5
DOI 10.1016/j.medj.2024.03.007, PubMed 38579729

Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic V et al. (2024)
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
Lancet (in press)
DOI 10.1016/S0140-6736(24)01315-1, PubMed 38971175

Damek A, Kurch L, Franke FC, Attarbaschi A, Beishuizen A, Cepelova M, Ceppi F, Daw S, Dieckmann K, Fernández-Teijeiro A, Feuchtinger T, Flerlage JE, Fosså A, Georgi TW, Hasenclever D, Hraskova A, Karlen J, Klekawka T, Kluge R, Körholz D, Landman-Parker J, Leblanc T, Mauz-Körholz C, Metzler M, Pears J et al. (2024)
Hodgkin lymphoma: hypodense lesions in mediastinal masses
Sci Rep, 14 (1), 14591
DOI 10.1038/s41598-024-64253-8, PubMed 38918503